ArticleBMJ open2023

Patient-reported well-being in value-based care using tildrakizumab in a real-world setting: protocol of a multinational, phase IV, 1-cohort prospective observational study (the POSITIVE study).

Matthias Augustin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.